Our work indicated that HOXA7 is a potential prognostic biomarker for KRAS mutant CRC, and targeting the oncogenic loop may provide a promising therapeutic strategy for HOXA7-mediated KRAS mutant CRC metastasis. The gene discussed is KRAS; the disease is colorectal carcinoma.